ALN-TTR02: Completed Phase I enrollment

Alnylam completed enrollment of 17 healthy volunteers in a single-blind, placebo-controlled, U.K. Phase I trial evaluating single ascending-doses of 0.01-0.50 mg/kg IV ALN-TTR02. ...